



ORIGINAL ARTICLE

Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents



Mohamed F. Zayed^{a,b,*}, Memy H. Hassan^{c,d}

^a Department of Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia

^b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

^c Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

^d Department of Pharmacy, College of Medical Rehabilitation Sciences, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia

Received 7 January 2013; accepted 29 March 2013

Available online 6 April 2013

KEYWORDS

Quinazolinone;
Antibacterial;
Anti-inflammatory;
Sulfonamides;
Diiodo;
Synthesis

Abstract Some novel 6,8-diiodo-2-methyl-3-substituted-quinazolin-4(3H)-ones bearing sulfonamide derivatives (4–11) were synthesized in good yields and evaluated for their possible antibacterial, anti-inflammatory activities and acute toxicity. The structures of the synthesized compounds were confirmed on the basis of their spectral data and elemental analysis. Their antibacterial activities were evaluated by the agar well diffusion method while their anti-inflammatory activities were evaluated by the carrageenan-induced hind paw edema test. All the tested compounds showed considerable antibacterial activities and high to moderate anti-inflammatory activities that last for 12 h compared to ibuprofen. All the tested compounds showed no toxic symptoms or mortality rates 24 h post-administration at tested anti-inflammatory doses. In addition, LD₅₀ for all tested compounds was higher than that for ibuprofen implying their good safety margin. The obtained results showed that the most active compounds could be useful as a template for future design, modification and investigation to produce more active analogs.

© 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.

* Corresponding author. Address: Department of Pharmaceutical Chemistry, College of Pharmacy, Taibah University, P.O. Box 344, Al-Madinah Al-munawarah 41477, Saudi Arabia. Tel.: +966 598821047; fax: +966 48475027.

E-mail address: mfzayed25@yahoo.com (M. F. Zayed).

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

1. Introduction

There is a strong relationship between bacterial infection and inflammation (Sy et al., 2011). Bacterial infection often produces pain and inflammation. Inflammation remains a common with poorly controlled clinical problem which can be life threatening in extreme form of allergy, autoimmune diseases and rejection of transplanted organs (Gounon and Huerre, 1996). The treatment options which can be used for inflammatory diseases are unsatisfactory and complicated


due to their lack of efficacy and adverse effect profile. It seemed worthwhile to look for candidates acting on more than one pathway involved in inflammatory conditions (Bot et al., 2011).

Quinazolin-4-one ring system has been consistently rewarded as a promising molecule because of its broad spectrum of pharmaceutical activities like antihistaminic (Lemura et al., 1989), anti-inflammatory (Amin et al., 2010), antibacterial (Kini and Grover, 2006), antidiabetic (Ram et al., 2003), anticancer (Abbas et al., 2012), antifungal (Liu et al., 2006), anthelmintics (Connolly et al., 2005) and antiviral activities (Dinakaran et al., 2003). In addition to that, anti-inflammatory quinazolines possess remarkable anti-inflammatory activity through inhibition of tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6) (Rajan et al., 2010).

On the other hand, sulfonamide derivatives have been reported to possess significant antibacterial activities through competitive inhibition of dihydropteroate synthetase enzyme (DHPS) which is involved in folate synthesis (Skold, 2000). Moreover, some sulfonamides work as anti-inflammatory drugs like celecoxib which works as a COX-2 inhibitor (Gassani et al., 2010) and acetazolamide which works by diuretic mechanism (Jaiswal et al., 2004). On light of these findings, we planned to prepare the target compounds as hybrid molecules. These molecules contain the quinazolinone ring system and fused with sulfonamide derivatives to form a group of compounds resembling and collecting both features of nitrogen heterocyclic moiety and sulfonamide moiety. In addition, iodine atoms exist at 6th and 8th positions from quinazolinone nucleus. Iodine was selected because it has received considerable attention in organic synthesis due to its high tolerance to air and moisture, low-cost, nontoxic nature and ready availability. Presence of iodine increases the lipophilicity of the molecules, the surface of contact, the absorption and the distribution (Laznicek et al., 1985; Yanming et al., 2003).

1.1. Rationale of the study

A literature survey revealed that the presence of quinazolinone moiety, which can undergo substitution at the heteroatom or the distal aromatic ring, is a necessary requirement for the antibacterial and anti-inflammatory activities such as compounds [A] (Kini and Grover, 2006), [B] (Ali et al., 2010) and [C] (Pan-neerselvam et al., 2009). Moreover, quinazolinone derivatives with the appropriate substituent mainly amine or substituted amine at 4th position and either halogen or electron rich substituent at 6th or 8th position are known to promote against bacteria and inflammation (Tiwari et al., 2006). In view of the previous rationale, it was thought worthwhile to study the effects of two pharmacophoric moieties like quinazolinone and sulfonamide in a single molecule on the antibacterial and anti-inflammatory activities. The target compounds have been designed to contain different substituents with different electronic environments. As shown in Scheme 1, these substituents joined to the fixed moiety (3) start with hydrogen from sulfanilamide in compound (4), acetamide from sulfacetamide in compound (5), benzamide from sulfabenzamide in compound (6), pyridine from sulfapyridine in compound (7), pyrimidine from sulfadiazine in compound (8), 5-methylisoxazole from sulfamethoxazole in compound (9), 4,6-dimethylpyrimidin from sulfamethazine in compound (10) and 3,4-dimethyl-1,2-oxazole from sulfafurazole in compound (11). These varied substituents allow us to study the effect of hydrophilic and hydrophobic



Scheme 1 Synthesis of the target compounds (4–11).




Figure 1 Similarities between reported compounds as antibacterial, anti-inflammatory and target compounds (4–11).

changes on the biological activity of the target compounds. Fig. 1 represents the similarities between the reported antibacterial and anti-inflammatory quinazolinones and our designed compounds.

2. Materials and methods

2.1. Chemistry

The tested compounds were analyzed at the Analytical Center, College of Science, Cairo University, Egypt. All melting points were measured on a Griffin melting point apparatus (Griffin) and are uncorrected. The Infrared spectra were recorded as KBr disks on a Nicolet IR 200 (Thermo Fisher Scientific). The ¹HNMR and ¹³CNMR spectra were run using TMS as an internal standard (Sigma–Aldrich) on Varian Mercury VXR-300 NMR (Varian). Mass spectra were obtained on a JEOL-SX-102 instrument using electron impact ionization. Elemental analyses (C, H, N) were performed on a Perkin–Elmer 240C analyzer (Perkin–Elmer). All compounds were within $\pm 0.4\%$ of the theoretical values. All chemicals used for synthesis were purchased from (Sigma–Aldrich).

2.2. Synthesis

The synthetic strategy to prepare the target compounds (4–11) is depicted in Scheme 1: it includes two simple reactions, first one is the acetylation/benzylation followed by the ring closure reaction for 2-amino-3,5-diiodobenzoic acid (1). Compound (1) when refluxed with acetic anhydride for one hour converted into benzoxazinone. This reaction afforded quantitative yield of 6,8-diiodo-2-methyl-4H-benzo[d][1,3]oxazin-4-one (2). Second reaction is a nucleophilic displacement reaction for the oxygen of benzoxazinone with the nitrogen of the amino group upon treating with sulfonamides. The second reaction was done by refluxing compound (2) with the appropriate sulfonamide in dry conditions for six hours to give sulfonamide derivatives of 6,8-diiodo-2-methyl-quinazolinone (4–11) in variable yields between 62% and 76%.

2.3. Pharmacology

2.3.1. Animals

The animals were procured from the Animal House Center, College of Pharmacy, King Abdulaziz University, Saudi Arabia, and were maintained in a colony cages at $25 \pm 2^\circ\text{C}$, relative humidity of 45–55%, under 12 h light and dark cycles; they were fed standard animal feed. All animals were acclimatized for a week before use. The protocol adopted for the experimentation of animals was approved by the Institutional Animal Ethics Committee (approval No: 409/432). All the experiments were carried out according to the respective internationally valid guidelines.

2.3.2. Biological screening

All the newly synthesized compounds (4–11) were screened to evaluate their antibacterial and anti-inflammatory activities and acute toxicity. The antibacterial activity was performed by the agar well diffusion method while the anti-inflammatory activity was evaluated by the carrageenan induced rat Paw edema method using ibuprofen as a reference drug. The response of all the compounds to antibacterial activity is good however, some of the compounds showed promising anti-inflammatory activity. The other remaining compounds showed moderate anti-inflammatory activity. No toxic symptoms or mortality rates were observed 24 h post administration

implying their good safety margin. The details of activity results are outlined below.

2.3.3. Antibacterial activity

Antibacterial activity of all the test compounds was determined by agar well diffusion method (Waynae, 1997) which is recommended by the National Committee for Clinical Laboratory Standards (NCCLS) against two kinds of Gram positive micro organisms *Staphylococcus aureus* (MTCC 96) and *Staphylococcus epidermis* (MTCC 435) and two kinds of Gram negative micro organisms *Pseudomonas aeruginosa* (MTCC 741), and *Escherichia coli* (MTCC443) at 100 $\mu\text{g}/\text{mL}$ concentration using dimethylsulfoxide (DMSO) as a solvent. The bacteria were sub-cultured on Mueller Hinton agar medium. Streptomycin was used as a standard antibacterial under similar conditions at a concentration of 50 $\mu\text{g}/\text{mL}$ for comparison while solvent control was also maintained under similar conditions. The results of antibacterial screening are outlined in Table 1.

2.3.4. Acute toxicity

Toxicological studies of the synthesized compounds were performed using (LD_{50}) which is the dose that will kill 50% of the animal population within 24 h post treatment with the test substance. The toxicity test was performed using standard method in mice and rats (Ishii and Yoshikawa, 1993; Ecobichon, 1997; Upmanyu et al., 2011). When there is no information on a substance to be tested, for animal welfare reasons, it is recommended to use the starting dose of 300 mg/kg body weight. The animals were given the lowest dose of 300 mg/kg of the compounds at the first instance. Then the animals were observed for three days. They were treated orally with different doses of tested compounds (400, 600, 800, 1000, and 2000 mg/kg). The animals were then observed for 24 h for any behavioral effects such as nervousness, excitement, dullness, in-coordination or even death. Results for LD_{50} were calculated and are reported in Table 2.

2.3.5. Anti-inflammatory activity

Anti-inflammatory activity of all the test compounds was determined according to the reported method (Winter et al., 1962; Vogel, 2007) by carrageenan-induced hind paw edema test using ibuprofen as a standard drug. Briefly, Male or

Table 1 Antibacterial activity of tested compounds (4–11).

Compound ID	Gram positive strains		Gram negative strains	
	<i>S. aureus</i>	<i>S. epidermis</i>	<i>P. aeruginosa</i>	<i>E. coli</i>
4	20	21	18	22
5	17	19	20	20
6	14	18	14	17
7	18	20	15	20
8	19	17	21	19
9	15	16	21	16
10	13	15	20	21
11	19	18	21	19
Streptomycin (standard)	21	23	24	29

Inhibitory zone diameters in mm; conc of standard 50 $\mu\text{g}/\text{ml}$, compounds 100 $\mu\text{g}/\text{ml}$.

Table 2 Acute toxicity studies in mice and rats.

Compound No	$\text{LD}_{50}(\text{mg}/\text{kg})$	
	Mice	Rats
4	1015	950
5	974	844
6	1300	1245
7	1136	1020
8	1035	985
9	1554	1470
10	1633	1580
11	1670	1513
Ibuprofen (standard)	750	650

LD_{50} : dose that kills 50% of animals within 24 h after drug administration.

Table 3 Anti-inflammatory activity and duration of tested compounds at 50 mg/kg using carrageenan induced rat paw edema method.

Compound ID	Percent protection		
	3 h	6 h	12 h
4	39.14 ± 0.02 ^{*,**}	56.26 ± 0.04 ^{*,**}	51.41 ± 0.24 ^{*,**}
5	41.75 ± 0.65 ^{*,**}	62.83 ± 0.61 ^{*,**}	58.15 ± 0.06 ^{*,**}
6	27.2 ± 0.01 ^{*,**}	38.15 ± 0.04 ^{*,**}	36.41 ± 0.25 ^{*,**}
7	36.58 ± 0.47 ^{*,**}	44.62 ± 0.09 ^{*,**}	49.71 ± 0.34 ^{*,**}
8	27.92 ± 0.3 ^{*,**}	41.14 ± 0.07 ^{*,**}	39.61 ± 0.67 ^{*,**}
9	23.27 ± 0.71 ^{*,**}	31.34 ± 0.06 ^{*,**}	35.78 ± 0.86 ^{*,**}
10	20.56 ± 0.03 ^{*,**}	27.47 ± 0.03 ^{*,**}	34.58 ± 0.43 ^{*,**}
11	19.25 ± 0.71 ^{*,**}	28.16 ± 0.02 ^{*,**}	25.52 ± 0.6 ^{*,**}
Ibuprofen (standard)	68.12 ± 0.61 [*]	69.91 ± 0.74 [*]	67.54 ± 0.07 [*]

^{*,**} Significant difference from negative control and ibuprofen (standard), respectively at $P < 0.0001$, using Tukey's test as post ANOVA test.

female rats are starved overnight. To insure uniform hydration, the rats received 5 ml of water by stomach tube (controls), standard ibuprofen (25, 50 and 100 mg/kg), or test compounds (25, 50, 100 and 200 mg/kg) suspended in the same volume. One hour later, the rats were challenged by a subcutaneous injection of 0.1 ml of 1% solution of carrageenan (Sigma–Aldrich) into the plantar side of the left hind paw. The thickness of dorso-ventral diameter of each rat was measured using a pair of dial thickness gauge calipers accurate to 0.001 cm³ (Progressive Trading Corporation) 3, 6 and 12 h after induction of inflammation. The increase of paw volume after 3, 6 and 12 h was calculated as percentage compared with the volume measured immediately after injection of the irritant for each animal (0 h). Effectively treated animals show much less edema. The percentage of anti-inflammatory activity (% inhibition of inflammation) was calculated according to the following equation:

$$\% \text{inhibition} = (Lc - Lt/Lc) \times 100$$

Lt is the mean increase in paw thickness in rats treated with the tested compounds and Lc is the mean increase in paw thickness in control group.

Evaluation: The difference at the various time intervals gives some hints for the duration of the anti-inflammatory effect for each compound as reported in Table 3. Doses that

Table 4 ED₅₀ and Relative potency of tested compounds to Ibuprofen at 6 h.

Compound ID	ED ₅₀ (mg/kg)	Relative potency
4	60	0.66
5	54	0.74
6	90	0.44
7	69	0.58
8	75	0.53
9	105	0.38
10	120	0.33
11	117	0.34
Ibuprofen (standard)	40	1.00

ED₅₀ is the dose required to induce 50% inhibition of rat paw edema (50% anti-inflammatory effect).

ED₅₀ was calculated using instate program by plotting results at all doses levels; Ibuprofen was tested at a dose range from 25 to 100 mg/kg and tested compounds from 25 to 200 mg/kg.

exhibited 50% protection in addition to the relative potencies of the test compounds to ibuprofen were recorded for comparisons and are shown in Table 4.

3. Results

Antibacterial assay of all the test compounds (4–11) showed good activities against both of Gram positive bacteria and Gram negative bacteria. These activities were ranged from 61.91% up to 95.23% from the activity of the standard. The activity data generated are tabulated in Table 1. The anti-inflammatory screening showed that compounds (6, 7, 8, 9, 10 and 11) were considered to have moderate anti-inflammatory activity however, compounds (4 and 5) showed considerable inhibition as shown in Tables 3 and 4. No toxic symptoms or mortality rates were observed 24 h post-administration at all suggested therapeutic doses however, the LD₅₀ for most of tested compounds is much higher than that reported for ibuprofen. Concerning other actions, compounds 7, 8 and 11 induced urination while compounds 4, 5 and 6 induced sedation, calmness, muscle relaxation and decreased respiration.

4. Discussion

Inspection of the chemical structure of the target compounds suggested that target compounds could be divided into two subunits: the quinazolinone part and the sulfonamide part (Fig. 1). The two parts have been reported to have significant broad spectrum of antibacterial activities which might contribute to the good results obtained from testing them as antibacterial agents. Moreover, substitution of the distal aromatic ring from quinazolinone moiety with iodine at 6th and 8th positions might also helped in obtaining such good results.

For the anti-inflammatory activity, compounds with aliphatic side chain (4) and (5) were more active than that with aromatic one. Compound (5), the most active compound among all the test compounds, contains aliphatic side chain. The relative potency of this compound was 74% of the reference's potency, as shown in Table 4. Pyridine containing compound (7) was more active than those with pyrimidine or oxazole instead. Within the pyrimidine and oxazole derivatives, dimethylated derivatives (10) and (11) were less active

than monomethylated one (9) and methyl free one (8). The results of acute toxicity test which have been done to all test compounds indicated to their good safety margin. Although the title compounds exhibited potent antibacterial and anti-inflammatory actions, moderate anti-inflammatory activity was found. Hence, necessary structural modifications are planned in the future study to increase the anti-inflammatory activity. In general, the present study showed that compound (5) was the most active compound with combined ability to inhibit bacterial infection and inflammation. This compound could therefore serve as a lead molecule for further modification to obtain clinically useful antibacterial and anti-inflammatory agents.

5. Conclusion

We have synthesized and tested some novel 6,8-diiodo-2-methyl-3-substituted-quinazolin-4(3H)-ones derivatives for their antibacterial and anti-inflammatory activities. All compounds induced significant antibacterial activity. Two compounds showed promising anti-inflammatory activity while the other five compounds showed moderate anti-inflammatory activity. All Compounds were tested for acute toxicity and showed good safety margin.

6. Experimental

6.1. Chemistry

6.1.1. 6,8-Diiodo-2-methyl-4H-benzo[d][1,3]oxazin-4-one (2)

It was prepared by refluxing (3.88 gm, 0.01 mol) of 2-amino-3,5-diiodobenzoic acid (1) with the appropriate amount of acetic anhydride for one hour. The residue obtained was evaporated till complete dryness, left to cool, washed with petroleum ether many times, collected, filtered and dried well in the absence of moisture.

Yield 85%, mp: 185–187 °C; ¹HNMR (DMSO-d₆): δ 1.21 (s, 3H, CH₃) 7.21–8.19 (m, 2H, Ar–H). ¹³C NMR (DMSO-d₆): δ 24.23, 82, 90.5, 118.5, 138.2, 149.6, 150, 154.1, 158. Anal. Calcd. for C₉H₅I₂NO₂ (412.84): C, 26.18; H, 1.22; N, 3.39. Found C, 26.32; H, 1.01; N, 3.74. MS (EI) *m/z* 413.8 [M + 1].

6.1.2. General method for preparation of test compounds (4–11)

They were prepared in a conical flask by mixing (0.01 mol, 4.13 gm) of compound (2) with the appropriate amount (0.01 mol) of sulfonamide derivatives in 100 ml dry pyridine, refluxed for six hours, cooled then treated with few amounts of 10% hydrochloric acid and poured onto crushed ice. The obtained crystals were collected by filtration and re-crystallized from ethanol or glacial acetic acid. The melting points for all synthesized compounds were above 300 °C.

6.1.3. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)benzenesulfonamide (4)

Yield 73%, ¹HNMR (DMSO-d₆): δ 2.26 (s, 3H, CH₃), 5.3 (s, 2H, NH₂), 6.96–7.77 (m, 6H, Ar–H). ¹³C NMR (DMSO-d₆): δ 48.2, 82.3, 91.4, 120.5, 121.9, 125, 192.7, 134.5, 142.7, 145.1, 149.4, 157.2, 164. Anal. Calcd. for C₁₅H₁₁I₂N₃O₃S (566.88): C, 31.77; H, 1.95; N, 7.41. Found C, 31.61; H, 1.81; N, 7.29. MS (EI) *m/z* 567.8 [M + 1].

6.1.4. N-(4-(6,8-diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)phenylsulfonyl)acetamide (5)

Yield 70%, ¹HNMR (DMSO-d₆): δ 2.21 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 7.01–8.12 (m, 6H, Ar–H), 8.4 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 24.5, 48, 85.4, 93.7, 123.5, 128, 135, 137.5, 141.7, 149.2, 159.2, 166, 175.4. Anal. Calcd. for C₁₇H₁₃I₂N₃O₄S (608.87): C, 33.52; H, 2.15; N, 6.90. Found C, 33.43; H, 1.98; N, 7.12. MS (EI) *m/z* 609.8 [M + 1].

6.1.5. N-(4-(6,8-diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)phenylsulfonyl)benzamide (6)

Yield 76%, ¹HNMR (DMSO-d₆): δ 2.33 (s, 3H, CH₃), 6.71–8.26 (m, 11H, Ar–H), 8.37 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 48.51, 84.9, 95.3, 121.5, 123.2, 127.5, 128.3, 129, 132.6, 134.3, 135, 137.6, 140.7, 146.2, 154.9, 163, 172.2. Anal. Calcd. for C₂₂H₁₅I₂N₃O₄S (670.89): C, 39.36; H, 2.25; N, 6.26. Found C, 39.51; H, 2.47; N, 6.47. MS (EI) *m/z* 671.8 [M + 1].

6.1.6. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-(pyridin-2-yl)benzenesulfonamide (7)

Yield 68%, ¹HNMR (DMSO-d₆): δ 2.42 (s, 3H, CH₃), 6.92–8.15 (m, 10H, Ar–H), 8.27 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 48.71, 82.9, 93.2, 112.2, 120.4, 122.2, 128.3, 129, 136.6, 139, 140.7, 141.2, 147.1, 148, 152.4, 155.9, 162. Anal. Calcd. for C₂₀H₁₄I₂N₄O₃S (643.89): C, 37.29; H, 2.19; N, 8.70. Found C, 37.12; H, 2.37; N, 8.93. MS (EI) *m/z* 644.8 [M + 1].

6.1.7. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-(pyrimidin-2-yl)benzenesulfonamide (8)

Yield 65%, ¹HNMR (DMSO-d₆): δ 2.35 (s, 3H, CH₃), 7.02–8.35 (m, 9H, Ar–H), 8.41 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 48.15, 81.2, 114, 122, 126.4, 128, 129.4, 138, 140.7, 146.2, 154, 158, 160.7, 170. Anal. Calcd. for C₁₉H₁₃I₂N₃O₃S (644.88): C, 35.37; H, 2.03; N, 10.85. Found C, 35.64; H, 2.33; N, 10.75. MS (EI) *m/z* 645.8 [M + 1].

6.1.8. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (9)

Yield 70%, ¹HNMR (DMSO-d₆): δ 2.32 (s, 3H, CH₃), 2.46 (s, 3H, CH₃), 7.21–8.14 (m, 7H, Ar–H), 8.31 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 14.5, 48.57, 85.2, 92, 96, 122, 124.6, 129.3, 136, 136.2, 140, 146.8, 150, 154, 156.5, 160, 171.3. Anal. Calcd. for C₁₉H₁₄I₂N₄O₄S (647.88): C, 35.20; H, 2.18; N, 8.64. Found C, 35.16; H, 2.41; N, 8.54. MS (EI) *m/z* 648.8 [M + 1].

6.1.9. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (10)

Yield 66%, ¹HNMR (DMSO-d₆): δ 2.41 (s, 3H, CH₃), 2.52 (s, 6H, 2CH₃), 6.91–7.98 (m, 7H, Ar–H), 8.21 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 28, 49, 86.4, 95.1, 112, 121, 126.6, 130, 138, 138.2, 144, 148.2, 158, 162.4, 164, 175.3. Anal. Calcd. for C₂₁H₁₇I₂N₅O₃S (672.91): C, 37.46; H, 2.55; N, 10.40. Found C, 37.29; H, 2.77; N, 10.54. MS (EI) *m/z* 673.9 [M + 1].

6.1.10. 4-(6,8-Diiodo-7-methyl-4-oxoquinazolin-3(4H)-yl)-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide (11)

Yield 62%, ¹HNMR (DMSO-d₆): δ 2.31 (s, 6H, 2CH₃), 2.43 (s, 3H, CH₃) 7.03–8.17 (m, 6H, Ar–H), 8.36 (s, 1H, NH) ¹³C NMR (DMSO-d₆): δ 7.5, 10.8, 48.92, 86, 93.1, 102, 123, 125.2, 129.5, 136, 136.4, 140, 146.2, 149, 156.1, 157, 159.4,

162. Anal. Calcd. for $C_{20}H_{16}I_2N_4O_4S$ (661.90): C, 36.27; H, 2.44; N, 8.46. Found C, 36.49; H, 2.65; N, 8.61. MS (EI) m/z 662.9 [M + 1].

6.2. Statistical analysis

Data obtained were expressed as means. Statistical difference between the treated and the control groups was evaluated by One Way Analysis of Variance (ANOVA) followed by the Tukey's test as a post ANOVA multiple comparison test (Sigma Stat version 3; SPSS Inc.) to determine the statistical significance. A P value < 0.05 was considered statistically significant.

Acknowledgments

The authors extend their appreciation to the Deanship of Scientific Research at Taibah University for funding the work through the research group project No (409/432).

References

- Abbas, E.S., Awadallah, M.F., Ibrahim, A.N., Said, G.E., Kamel, M.G., 2012. New quinazolinone-pyrimidine hybrids: synthesis, anti-inflammatory, and ulcerogenicity studies. *Eur. J. Med. Chem.* 53, 141–149.
- Ali, M.M., Mohamed, A.Yahia, El-Bayouki, M.A.K., Basyouni, M.W., Abbas, Y.S., 2010. Synthesis of some new 4(3H)-quinazolinone-2-carboxaldehyde thiosemicarbazones and their metal complexes and a study on their anticonvulsant, analgesic, cytotoxic and antimicrobial activities. *Eur. J. Med. Chem.* 45, 3365–3373.
- Amin, M.K., Kamel, M.M., Anwar, M.M., Khedr, M., Syam, M.Y., 2010. Synthesis, biological evaluation and molecular docking of novel series of spiro [2H,3H] quinazolinone-2,1'-cyclohexan]-4(1H)-one derivatives as anti-inflammatory and analgesic agents. *Eur. J. Med. Chem.* 45, 2117–2131.
- Bot, M., Carney, M.R., Freedland, E.K., Rubin, H.E., Rich, W.M., Steinmeyer, C.B., Mann, L.D., 2011. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. *J. Psychosom. Res.* 71, 13–17.
- Connolly, J.D., Cusack, D., Sullivan, P.T., Guiry, J.P., 2005. Synthesis of quinazolinones and quinazolines. *Tetrahedron* 61, 10153–10202.
- Dinakaran, M., Selvam, P., Declercq, E., Sridhar, S.K., 2003. Synthesis, antiviral and cytotoxic activity of 6-bromo-2,3-disubstituted-4(3H)-quinazolinones. *Biol. Pharm. Bull.* 26, 1278–1282.
- Ecobichon, D.J., 1997. *The Basis of Toxicology Testing*. CRC Press, New York (pp. 43–86).
- Gassani, A.B., Rezende, M.R., Lima, P.P., Alves, L.D., dosreis, G.W., Bakhle, S.Y., Francischi, N.J., 2010. Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? *Pharmacol. Res.* 62, 439–443.
- Gounon, P., Huerre, R.M., 1996. Inflammation: patterns and new concepts. *Res. Immunol.* 147, 417–434.
- Ishii, R., Yoshikawa, K., 1993. Microbial bioassay of acute toxicity by the pH inhibition method and comparison of IC_{50} (pHI) with LD_{50} for rats and mice. *J. Biosci. Bioeng.* 76, 361–366.
- Jaiswal, M., Khadikar, V.P., Supuran, T.C., 2004. Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzenesulfonamides: a molecular connectivity approach. *Bioorg. Med. Chem. Lett.* 14, 5661–5666.
- Kini, G.S., Grover, G., 2006. Synthesis and evaluation of new quinazolinone derivatives of nalidixic acid as potential antibacterial and antifungal agents. *Eur. J. Med. Chem.* 41 (2), 256–262.
- Laznickek, M., Beno, P., Waissner, K., Kvetina, J., 1985. Quantitative chemical structure-pharmacokinetic data relationships. IV. Relationships between pharmacokinetic data and lipophilicity of iodine-substituted aromatic and arylaliphatic compounds. *Cesko. Farm.* 34, 353–358.
- Lemura, R., Manabe, H., Todayaki, S., 1989. Bioisosteric transformation of H1-antihistaminic benzimidazole derivatives. *Chem. Pharm. Bull.* 37, 2723–2726.
- Liu, J., Wilson, J.C., Ye, P., Sprague, K., Sargent, K., Si, Y., Beletsky, G., Yohannes, D., Chung, S., 2006. Privileged structure based quinazolinone natural product-templated libraries: identification of novel tubulin polymerization inhibitors. *Bioorg. Med. Chem. Lett.* 16, 686–690.
- Panneerselvam, P., Rather, A.B., Reddy, S.R.D., Kumar, R.N., 2009. Synthesis and anti-microbial screening of some Schiff bases of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones. *Eur. J. Med. Chem.* 44, 2328–2333.
- Rajan, S.G., Hardik, M.T., Tony, G., Jill, W., Donna, R., Kamala, K.V., Vasudevan, S., 2010. Design, synthesis and evaluation of novel 2-thiophen-5-yl-3H-quinazolin-4-one analogues as inhibitors of transcription factors NF- κ B and AP-1 mediated transcriptional activation: their possible utilization as anti-inflammatory and anti-cancer agents. *Bioorg. Med. Chem. Lett.* 18, 2796–2808.
- Ram, V.J., Farhanullah, Tripathi, B.K., Srivastava, A.K., 2003. Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones. *Bioorg. Med. Chem.* 1, 2439–2444.
- Skold, O., 2000. Sulfonamide resistance: mechanisms and trends. *Drug Resist. Update* 3, 155–160.
- Sy, M., Kitazawa, M., Medeiros, R., Whitman, L., Cheng, D., Lane, E.T., Laferla, M.F., 2011. Inflammation induced by infection potentiates tau pathological features in transgenic mice. *Am. J. Pathol.* 178, 2811–2822.
- Tiwari, A.K., Mishra, A.K., Bajpai, A., Mishra, P., Sharma, R.K., Pandey, V.K., Singh, V.K., 2006. Synthesis and pharmacological study of novel pyrido-quinazolinone analogues as anti-fungal, antibacterial, and anticancer agents. *Bioorg. Med. Chem. Lett.* 16, 4581–4585.
- Upmanyu, N., Gupta, J.K., Shah, K., Mishra, P., 2011. Anti-inflammatory and antinociceptive evaluation of newly synthesized 4-(substituted ethanoyl) amino-3-mercapto-5-(4-methoxy) phenyl-1,2,4-triazoles. *J. Pharm. Bioall. Sci.* 3 (2), 259–265.
- Vogel, G.H., 2007. *Drug Discovery and Evaluation Pharmacological Assays*, second ed. Springer-Verlag, New York.
- Waynae, P.A., 1997. National Committee for Clinical Laboratory Standards approved Standards M2–A6. Performance Standards for Antimicrobial Disc Susceptibility Testing, sixth ed. Perseus, Cambridge.
- Winter, C.A., Risely, E.A., Nuss, G.W., 1962. Carrageenin-induced edema in hind paw of the rat an assay for anti-inflammatory drugs. *Proc. Soc. Exp. Biol. Med.* 111, 544–547.
- Yanming, W., Chester, A.M., Guo-Feng, H., Manik, L.D., Daniel, P.H., Li, S., 2003. Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives. *J. Mol. Neurosci.* 20, 255–260.